1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Recurrent Colorectal Adenocarcinoma: new trials by email Literature Review of Recurrent Colorectal Adenocarcinoma trials Research Report on Recurrent Colorectal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-06-05 | 2026-09-23 |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride - Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2019-12-27 | 2026-02-10 |
Colorectal Neoplasms (2) · Colonic Neoplasms (1) · Rectal Neoplasms (1)
Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Rectal Diseases (2)
(225)Ac-DOTA-c(RGDyK) (1) · Bevacizumab (1) · Biopsy (1) · Cetuximab (1) · Disulfides (1) · Irinotecan (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · Thymidine (1) · Trifluridine (1) · encorafenib (1) · trifluridine tipiracil drug combination (1)
National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1)
United States (2)
Christos Fountzilas, MD (1) · Salvador Alonso Martinez (1)
PMID 39244627, PMID 40611889, PMID 42101296
UM1CA186688 (1)